<?xml version="1.0" encoding="UTF-8"?>
<p>Importantly, a systematic review of the current evidence for non-steroidal anti-inflammatory drugs (NSAIDs) in the management of COVID-19 suggests that naproxen may be worthy of further investigation in clinical trials, because of its positive effects in controlling the symptoms of coryza, rhinovirus infection and influenza-related pneumonia
 <xref rid="CIT0044" ref-type="bibr">
  <sup>44</sup>
 </xref>. On the other hand, the inhibitory activity of saquinavir against SARS-CoV-2 3CLpro denoted in this study matched the result from 
 <italic>in silico</italic> molecular docking models reported previously
 <xref rid="CIT0045" ref-type="bibr">
  <sup>45</sup>
 </xref>. Furthermore, sirolimus, a moderate SARS-CoV-2 3CLpro inhibitor identified in this study, was suggested to help prevent progression to severe forms of COVID-19 by mitigating the SARS-CoV-2-induced cytokine storm
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0046" ref-type="bibr">
  <sup>46</sup>
 </xref>. Last, but not least, bexarotene, a moderate SARS-CoV-2 3CLpro inhibitor, was shown to have broad-spectrum anticoronavirial activity in a study published recently
 <xref rid="CIT0047" ref-type="bibr">
  <sup>47</sup>
 </xref>.
</p>
